Canada - English - Health Canada

eli lilly canada inc - dulaglutide - solution - 0.75mg - dulaglutide 0.75mg - incretin mimetics

Canada - English - Health Canada

eli lilly canada inc - dulaglutide - solution - 1.5mg - dulaglutide 1.5mg - incretin mimetics

Canada - English - Health Canada

eli lilly canada inc - dulaglutide - solution - 3mg - dulaglutide 3mg

Canada - English - Health Canada

eli lilly canada inc - dulaglutide - solution - 4.5mg - dulaglutide 4.5mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dulaglutide (unii: wtt295hsy5) (dulaglutide - unii:wtt295hsy5) - trulicity® is indicated: - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. - to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. limitations of use trulicity: - has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - should not be used in patients with type 1 diabetes mellitus. - has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see warnings and precautions (5.6)] . trulicity is contraindicated in patients with: - personal or family history of medullary thyroid carcino

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dulaglutide (unii: wtt295hsy5) (dulaglutide - unii:wtt295hsy5) - trulicity® is indicated: - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. - to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. limitations of use trulicity: - has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - should not be used in patients with type 1 diabetes mellitus. - has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see warnings and precautions (5.6)] . trulicity is contraindicated in patients with: - personal or family history of medullary thyroid carcino

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - dulaglutide - solution for injection - 1.5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - dulaglutide - solution for injection - 3mg/1ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - dulaglutide -

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

eli lilly and company - dulaglutide - solution for injection - 0,75mg/0.5ml